Current progress in the study of acute myeloid leukemia

被引:2
|
作者
Yestemirova, G. A. [1 ]
Yessimsiitova, Z. B. [1 ]
Danilenko, M. P. [2 ]
机构
[1] Al Farabi Kazakh Natl Univ, Alma Ata, Kazakhstan
[2] Ben Gurion Univ Negev, Beer Sheva, Israel
来源
关键词
acute myeloid leukemia; cancer; anemia; FLT3; flavopyridol; HDAC inhibitor; PAP; targeted therapy; HEALTH-ORGANIZATION CLASSIFICATION; 2016; REVISION; DIFFERENTIATION;
D O I
10.26577/ijbch-2019-v2-11
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In recent years the rate of malignant diseases has been growing rapidly around the world. The Republic of Kazakhstan, according to international statistics, refers to the countries with moderately high cancer incidence and mortality. Every year approximately thirty thousand Kazakhstani people are diagnosed with cancer. In 2018, 35,753 patients were registered in the country, of which 44.3% were men and 55.7% were women. Cancer mortality over the same period amounts to about 15,000 lives. The cancer incidence rate increased by 8% from 181.2 (in 1999) to 195.7 per 100,000 population in 2019 [1]. Blood cancers are relatively rare diseases but, nevertheless, in Kazakhstan about 7,000 patients with hematopoietic malignancies are currently registered. Therefore, our knowledge of recent advances in hemato-oncology is highly relevant for successful therapy of these malignancies. In this review we provide information on the subtypes, symptoms, diagnosis and treatment of acute myeloid leukemia (AML) - one of the most aggressive blood cancer.
引用
收藏
页码:86 / 92
页数:7
相关论文
共 50 条
  • [21] Treatment of acute myeloid leukemia: are we making progress?
    Burnett, Alan K.
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2012, : 1 - 6
  • [22] Research progress on molecular biomarkers of acute myeloid leukemia
    Yin, Pei-Yuan
    Wang, Rui-Wen
    Jing, Rui
    Li, Xing
    Ma, Jing-Hua
    Li, Kai-Min
    Wang, Hua
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [23] Current status of immunotherapy in acute myeloid leukemia
    Subklewe, Marion
    [J]. HEMASPHERE, 2018, 2 : 15 - 18
  • [24] Acute myeloid leukemia Current understanding and management
    Becker, Michelle
    Farina, Kyle A.
    Mascarenhas, John
    [J]. JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2024, 37 (01): : 34 - 39
  • [25] Current strategies in immunotherapy for acute myeloid leukemia
    Lichtenegger, Felix S.
    Schnorfeil, Frauke M.
    Hiddemann, Wolfgang
    Subklewe, Marion
    [J]. IMMUNOTHERAPY, 2013, 5 (01) : 63 - 78
  • [26] Why Is Progress in Acute Myeloid Leukemia So Slow?
    Estey, Elihu
    [J]. SEMINARS IN HEMATOLOGY, 2015, 52 (03) : 243 - 248
  • [27] Current treatment options in acute myeloid leukemia
    Heuser, M.
    Schlenk, R. F.
    Ganser, A.
    [J]. INTERNIST, 2011, 52 (12): : 1386 - +
  • [28] Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges
    Shallis, Rory M.
    Wang, Rong
    Davidoff, Amy
    Ma, Xiaomei
    Zeidan, Amer M.
    [J]. BLOOD REVIEWS, 2019, 36 : 70 - 87
  • [29] STUDY OF THE INTERACTOME OF ACUTE MYELOID LEUKEMIA
    Ibanez, M.
    Carbonell-Caballero, J.
    Garcia-Alonso, L.
    Such, E.
    Barragan, E.
    Lopez-Pavia, M.
    LLop, M.
    Alonso, C.
    Montesinos, P.
    Sanz, M. A.
    Joaquin Cervera, Dopazo J.
    [J]. HAEMATOLOGICA, 2015, 100 : 2 - 3
  • [30] Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress
    Molica, Matteo
    Perrone, Salvatore
    Andriola, Costanza
    Rossi, Marco
    [J]. CANCERS, 2023, 15 (20)